Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies circulating cell-free tumor DNA testing to guide treatment with
regorafenib or TAS-102 in patients with colorectal cancer that has spread to other areas of
the body. Studying samples of blood from patients with colorectal cancer may help doctors
understand how well patients respond to treatment. Regorafenib and TAS-102 may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet
known how well ctDNA testing works in guiding treatment with regorafenib and TAS-102 for
patients with advanced or metastatic colorectal cancer.